Cantargia AB (FRA:7V3)
€ 0.1345 -0.0033 (-2.39%) Market Cap: 28.59 Mil Enterprise Value: 23.41 Mil PE Ratio: 0 PB Ratio: 6.87 GF Score: 38/100

Q3 2023 Cantargia AB Earnings Call Transcript

Nov 10, 2023 / 02:00PM GMT
Release Date Price: €0.295 (-10.01%)
Operator

This call is being recorded. Welcome to the Cantargia Q3 2023 report presentation. (Operator Instructions)

Now, I will hand over to the speakers: CEO, Göran Forsberg; and CFO, Patrik Renblad. Please go ahead.

GÃ;ran Forsberg
Cantargia AB - CEO

¶ -

Thanks a lot. It's been a very good period for Cantargia. And it's really a pleasure to present the progress we made in our projects at this Q3 report, as well as the financial updates.

So going directly into the story and what has happened -- so obviously, we presented new data in pancreatic cancer, which is the lead indication for nadunolimab, and we've seen -- and I'm coming back to that -- strong efficacy in general. But we also seen very strong effects in patients that have the highest levels of the target for our therapy, IL1RAP.

And we've done [digging the] further interviews to see that, for instance, IL1RAP is linked to KRAS mutations, which are associated with aggressive disease. So it gives us more and more confidence that the drug is really doing what it's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot